Colorectal Cancer Therapeutics Market 2024-2028: Size and Patent expiration of novel therapeutics; growth driven by the Type, Some of key Companies Positioned Strategically

The colorectal cancer therapeutics market size by Type (Targeted therapy, Immunotherapy, and Chemotherapy) and Geography (North America, Europe, Asia, and Rest of World (ROW)), is forecast to increase by USD 2001.8 million. The market is expected to grow at a CAGR of   4.5% between 2024 and 2028.

• In accordance with the World Trade Organization's TRIPS agreement, innovators are granted exclusive patent rights for 20 years from the filing date of their novel pharmaceutical therapeutics in the US and Europe. Consequently, pharmaceutical companies capitalize on this exclusivity by selling their high-priced, innovative biologics until patent expiration. However, the expiration of patents for significant colorectal cancer therapeutics, such as AVASTIN (bevacizumab), VECTIBIX (panitumumab), and ZALTRAP (ziv-Aflibercept), poses a challenge to the global colorectal cancer therapeutics market growth during the forecast period. The entry of biosimilars into the market post-patent expiration intensifies industry competition, ultimately leading to price decreases for the original biologic therapeutics.
• The colorectal cancer therapeutics market represents a significant business opportunity due to the increasing global burden of this disease. With a growing aging population and rising incidences of colorectal cancer, there is a pressing need for innovative and effective therapeutic solutions. Key players in this market are investing heavily in research and development to bring novel treatments to market, leveraging advanced technologies and targeted therapies to improve patient outcomes. The market is expected to grow robustly over the forecast period, driven by these trends and increasing healthcare spending.

Access the full report to know who are the other key countries segment-wise forecast and historic data

Some of the Key Companies:

• Accord Healthcare Ltd.
• Amgen Inc.
• Amneal Pharmaceuticals Inc.
• Bayer AG
• Biocon Ltd.
• Bristol Myers Squibb Co.
• CK Hutchison Holdings Ltd.
• Eli Lilly and Co.
• F. Hoffmann La Roche Ltd.
• Fresenius SE and Co. KGaA
• Hetero Drugs Ltd.
• Hikma Pharmaceuticals Plc
• Merck and Co. Inc.
• Ono Pharmaceutical Co. Ltd.
• Otsuka Holdings Co. Ltd.
• Pfizer Inc.
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/